The most common chronic rheumatic disease in children — a 2020 study combined genetic analysis across its several clinical subtypes and found 5 genome-wide significant risk loci, all represented on this page.
Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children: arthritis in one or more joints, starting before age 16 and lasting more than 6 weeks, with other causes ruled out. It is not one disease but a family of clinical subtypes (oligoarticular, polyarticular, systemic and others) grouped under one diagnostic umbrella because they share this basic definition.
López-Isac et al. 2020 ran a genome-wide association study (GWAS) specifically designed to analyze 3,305 European-ancestry cases against 9,196 controls combined across JIA's several clinical subtypes, rather than treating each subtype in isolation. It identified 5 genome-wide significant loci, all represented on this page: rs7647909 (FOXP1, odds ratio 1.17, p=2×10⁻⁹), rs4869314 (ERAP2, odds ratio 1.14, p=3×10⁻⁹), rs12430303 (TNFSF11, odds ratio 1.14, p=2×10⁻⁹), rs1051533 (ZFP36L1, odds ratio 1.16, p=1×10⁻⁸) and rs9960807 (near a non-coding region, odds ratio 1.28, p=3×10⁻¹⁴, the strongest of the 5).
The genes involved point toward immune regulation from more than one angle: FOXP1 and ERAP2 both have roles in immune cell development and antigen processing, and TNFSF11 (also known as RANKL) is directly involved in bone remodeling — a plausible mechanistic link to a disease that, left uncontrolled, can damage joints.
Juvenile idiopathic arthritis is diagnosed clinically — joint swelling or limited motion for more than 6 weeks in a child under 16, with other causes excluded — not by genotype. None of the 5 variants on this page are used by any guideline to diagnose JIA or decide treatment in an individual.
Treatment typically starts with NSAIDs and escalates to disease-modifying antirheumatic drugs (methotrexate is the most commonly used) for persistent disease, decided by clinical subtype and severity — not genotype. The 5 variants on this page describe population-level susceptibility found across JIA's subtypes combined; they do not change how an individual child is diagnosed or treated.
What a 23andMe/AncestryDNA export or raw VCF can and can't tell you about Juvenile Idiopathic Arthritis comes down to these specific, well-studied positions — not a diagnosis.
STAT4 · rs10174238
See detailed info →ATP8B2 · rs72698115
See detailed info →The studies behind these variants recruited participants from different ancestries — a result found in one population doesn't always transfer to another. Based on 7 of 7 linked studies with a resolved discovery ancestry.
Databases, guidelines and references
Juvenile idiopathic arthritis is the most common chronic rheumatic disease in children: arthritis starting before age 16 and lasting more than 6 weeks, with other causes ruled out. It covers several clinical subtypes under one diagnostic definition.
Analyzing 3,305 cases against 9,196 controls across JIA's clinical subtypes combined, it found 5 genome-wide significant loci: FOXP1, ERAP2, TNFSF11, ZFP36L1 and a fifth non-coding-region variant, each with a modest odds ratio between 1.14 and 1.28 per copy.
Not from what this page can confirm. The study analyzed subtypes combined, and the paywalled full text was not accessible to check whether any of these 5 loci is specific to one clinical subtype rather than shared across several.
No. Diagnosis is clinical -- joint swelling or limited motion persisting more than 6 weeks in a child under 16, with other causes excluded. Treatment follows clinical subtype and severity, not genotype.
Free to reuse. This page's text is original writing from freely-available research, licensed CC BY 4.0 — reuse it, including commercially, with attribution to MyGeneLog™. It's general research-derived information, not medical advice or a diagnosis — see Terms of Use.